Dr. Brooks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1010 Edgehill Rd N
Charlotte, NC 28207Phone+1 704-446-1900Fax+1 704-466-6084
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1976 - 1978
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1972 - 1974
Boston University Medical CenterResidency, Internal Medicine, 1970 - 1972
Harvard Medical SchoolClass of 1969
Certifications & Licensure
WI State Medical License 1982 - 2025
NC State Medical License 2008 - 2024
MD State Medical License 1976 - 1992- American Board of Internal Medicine Internal Medicine
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2020
Clinical Trials
- Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] Start of enrollment: 2001 Jan 01
- Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2011 Mar 01
- A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2011 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 4092 citationsEl Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosisBenjamin Rix Brooks, Robert G. Miller, Michael Swash, Theodore L. Munsat
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2000-12-01 - 304 citationsGlatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S. Wolinsky, Ponnada A. Narayana, Paul O'Connor, P. K. Coyle, Corey C. Ford
Annals of Neurology. 2007-01-01 - 32 citationsExtended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [cl...Kenneth P. Johnson, Benjamin Rix Brooks, J. A. Cohen, Corey C. Ford, Jonathan Goldstein
Neurology. 2001-12-01
Press Mentions
Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (Edaravone)August 15th, 2022- Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (Edaravone)June 29th, 2022
- #AAN2022 – US Real-World Data Show Radicava Boosts Survival RateApril 5th, 2022
- Join now to see all
Grant Support
- Tamoxifen Therapy On Mean Percent Predicted Isometric Strength In ALSNational Center For Research Resources2005
- Phase II Study Of Hu23f2g In Acute Excerbations Of Multiple SclerosisNational Center For Research Resources1998–2002
- Phase I Trial Of R-Methubdnf Given By Daily Injection To Patients With ALSNational Center For Research Resources1996
- Phase I Safety And Tolerability Study Of BDNF In Patients With ALSNational Center For Research Resources1995–1996
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
